论文部分内容阅读
Immunex公司开发的肿瘤坏死因子(TNF)受体融合蛋白Enbrel在治疗类风湿性关节炎的Ⅲ期临床试验中,结果良好,美国惠氏药厂决定支付Immunex公司1亿美元,以在美国和加拿大共同开发市场。1亿美元中,1500万美元用于进一步的工作,2000万美元用于FDA的新药注册(NDA)资料,3000万美元用于FDA审批。估计它能在1998年底得到FDA的批准。用于非重症类风湿性关节炎病人,市场约为2.5～5.0亿美元。该产品的竞争对手有Centocor公司开发的嵌合
Immunex’s Envelop, a Tumor Necrosis Factor (TNF) Receptor Fusion Protein Developed in a Phase III Clinical Trial for the Treatment of Rheumatoid Arthritis, Wyeth Pharmaceuticals Decides to Pay 100 Million U.S. Dollars to Immunex, Inc. Development of the market. Of the 100 million U.S. dollars, 15 million U.S. dollars are for further work, 20 million U.S. dollars for the FDA’s New Drug Registration (NDA) data, and 30 million U.S. dollars for FDA approval. It is estimated that it will be approved by the FDA by the end of 1998. For non-critical rheumatoid arthritis patients, the market is about 2.5 to 500 million US dollars. Competitors of this product have been developed by Centocor